MMIP represents the voice of medicines manufacturers in the UK. It was established jointly by the Government and the biopharmaceutical industry in 2014 to ensure that the UK is recognised by the global medicines industry as a world-class advanced centre for medicines manufacturing.

The UK's medicines industry is one of the country's leading manufacturing sectors, with exports worth around £30bn.

The Partnership aims to ensure that the UK continues to be an attractive place for this high-value industry to secure exports, provide high skilled job opportunities and contribute to solving the country's productivity puzzle. 

The UK Life Sciences Industrial Strategy recognised the sector’s high productivity and the MMIP is now an expert group under the direction of the Life Sciences Council. 

MMIP Structure 

Working closely with key government organisations including the Medicines and Healthcare products Regulatory Authority (MHRA), UK Trade and Investment (UKTI), Innovate UK and the Office for Life Sciences (OLS), MMIP is continuously working to sustain the UK's leading position in medicines manufacturing technologies, including those related to advanced therapy medicinal products (ATMPs), continuous production and digitalisation. 

Technology and Innovation Roadmap

During the second half of 2020, the Technology & Innovation workstream developed a roadmap, building on the MMIP mission, charting progress to date and describing how the continuing work of the MMIP will be organised under five ‘grand challenges’.

Workstreams 

MMIP is divided into six workstreams. All of these workstreams are supported by overarching communications work and building the manufacturing community to ensure it speaks with one voice. 

These workstreams are: 

• the technology and innovation landscape 
• the fiscal environment 
• the regulatory environment 
• the skills environment 
• Advanced Therapies manufacturing 

MMIP also works to build the medicines manufacturing community.  

Support 

MMIP is supported by the  ABPI, the BioIndustry Association (BIA) and the Knowledge Transfer Network, and includes leadership from Allergan Biologics, AstraZeneca, Eisai, FUJIFILM Diosynth Biotechnologies, GlaxoSmithKline, Pfizer and ReNeuron. It has a senior project director, employed by the ABPI, and additional dedicated resources provided by partners. 

Contact Us 

For more information please contact the MMIP Operations Team: 

• Dr Bryan Deane, New Medicines & Data Policy Director at the ABPI   
• MMIP Chair - Brian Henry